Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > NEW TRANSFER AGENT AS OF APRIL 11, 2024.

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Apr 05, 2024 3:09pm

127 Views

Post# 35973593

RE:NEW TRANSFER AGENT AS OF APRIL 11, 2024.

For all shareholders regarding receiving the voting information package, Odyssey Trust Company will be taking over from Computershare in sending out the information package. As of April 11th phone Odyssey to make sure you are showing as a shareholder of Replicel. It is disappointing but not surprising we are needing to find out this information ourselves.

Here is their contact information:

https://odysseytrust.com/

<< Previous

Bullboard Posts

Next >>

The Market Online’s Weekly Gold Report – Nov. 6, 2024